Primary Site >> Stomach Cancer
Gene >> ERBB4
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. PMID: 10535875 |
Ref: Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. PMID: 11360194 |
Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 |
Ref: High expression of HER3 is associated with a decreased survival in gastric cancer. PMID: 19047113 |
Ref: Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes. PMID: 20700725 Ref: Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. PMID: 20878069 |
Ref: Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. PMID: 21709195 Ref: The role of neuregulin4 and HER4 in gastrointestinal malignant lymphoma. PMID: 21805036 |
Ref: Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. PMID: 22135232 Ref: Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. PMID: 22371427 Ref: Frequent gene amplification predicts poor prognosis in gastric cancer. PMID: 22606006 |
Ref: [Clinical significance of human epidermal growth factor receptor family molecules expression in gastric cancer]. PMID: 23888453 |
Ref: Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. PMID: 23455716 Ref: A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. PMID: 24612546 Ref: Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. PMID: 24728052 Ref: The role of HER3 in gastric cancer. PMID: 25194439 Ref: High-density array comparative genomic hybridization detects novel copy number alterations in gastric adenocarcinoma. PMID: 25368240 |
Ref: Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. PMID: 25583476 Ref: Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. PMID: 25731189 |
Ref: Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. PMID: 26811494 Ref: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. PMID: 26874901 Ref: Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. PMID: 26919099 Ref: HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. PMID: 27069134 Ref: Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: A preliminary study. PMID: 27270314 Ref: HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis. PMID: 27536774 Ref: Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. PMID: 27787520 |
Ref: Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips. PMID: 28111342 Ref: miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting ERBB4 expression. PMID: 28501849 Ref: siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. PMID: 28881753 Ref: Immunohistochemical expression of CDX2, CK7, HER2 and HER4 in periampullary adenocarcinoma : implications for clinicopathology and patient outcomes. PMID: 29364095 Ref: Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival. PMID: 29872697 |
Ref: Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients. PMID: 28573357 Ref: 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation. PMID: 28851073 Ref: Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. PMID: 28859471 Ref: The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. PMID: 29535422 Ref: ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway. PMID: 29620274 Ref: Landscape of somatic mutations in gastric cancer assessed using next-generation sequencing analysis. PMID: 30250552 |